NCT00394836View on ClinicalTrials.gov

HuMax-CD20 i(Ofatumumab) n Follicular Lymphoma (FL) Patients Refractory to Rituximab

PHASE2CompletedINTERVENTIONAL
Enrollment

116

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

April 30, 2009

Study Completion Date

September 30, 2013

Conditions
Lymphoma, Follicular
Interventions
DRUG

Ofatumumab

Eight weekly infusions of ofatumumab. The first infusion of 300mg ofatumunab

DRUG

Ofatumumab

followed by 7 weekly infusions of 1000mg ofatumumab

Trial Locations (1)

SO16 6YD

GSK Investigational Site, Southampton

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00394836 - HuMax-CD20 i(Ofatumumab) n Follicular Lymphoma (FL) Patients Refractory to Rituximab | Biotech Hunter | Biotech Hunter